GDNF-expressing macrophages restore motor functions at a severe late-stage, and produce long-term neuroprotective effects at an early-stage of Parkinson's disease in transgenic Parkin Q311X(A) mice by Zhao, Y. et al.
GDNF-expressing Macrophages Restore Motor Functions at a 
Severe Late-stage, and Produce Long-Term Neuroprotective 
Effects at an Early-stage of Parkinson’s Disease in Transgenic 
Parkin Q311X(A) Mice
Yuling Zhao1,2, Matthew J. Haney1,2, Yeon S. Jin2, Olga Uvarov1,2, Natasha Vinod1,2, Yueh 
Z. Lee3, Benjamin Langworthy4, Jason P. Fine4, Myosotys Rodriguez5, Nazira El-Hage5, 
Alexander V. Kabanov1,2, Elena V. Batrakova1,2,*
1Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel 
Hill, North Carolina, USA
2Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina, USA
3Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 
USA
4Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina, USA
5Department of Immunology and Nano-medicine, Florida International University, Herbert 
Wertheim College of Medicine, Miami, FL, 33199, USA
Abstract
There is an unmet medical need in the area of Parkinson’s disease (PD) to develop novel 
therapeutic approaches that can stop and reverse the underlying mechanisms responsible for the 
neuronal death. We previously demonstrated that systemically administered autologous 
macrophages transfected ex vivo to produce glial cell line-derived neurotrophic factor (GDNF) 
readily migrate to the mouse brain with acute toxin-induced neuroinflammation and ameliorate 
neurodegeneration in PD mouse models. We hypothesized that the high level of cytokines due to 
inflammatory process attracted GDNF-expressing macrophages and ensured targeted drug delivery 
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to the PD brain. Herein, we validated a therapeutic potential of GDNF-transfected macrophages in 
a transgenic Parkin Q311X(A) mice with slow progression and mild brain inflammation. Systemic 
administration of GDNF-macrophages at a severe late stage of the disease leaded to a near 
complete restoration of motor functions in Parkin Q311X(A) mice and improved brain tissue 
integrity with healthy neuronal morphology. Furthermore, intravenous injections of GDNF-
macrophages at an early stage of disease resulted in potent sustained therapeutic effects in PD 
mice for more than a year after the treatment. Importantly, multiple lines of evidence for 
therapeutic efficacy were observed including: diminished neuroinflammation and α-synuclein 
aggregation, increased survival of dopaminergic neurons, and improved locomotor functions. In 
summary, GDNF-transfected macrophages represent a promising therapeutic strategy for PD at 
both late- and early-stages of the disease.
Graphical Abstract.
Autologous macrophages were transfected ex vivo to produce glial cell line-derived neurotrophic 
factor (GDNF) and intravenously injected into Parkin Q311(X)A mice. GDNF-expressing 
macrophages readily reach brain in PD mice; restore motor functions in transgenic mice at a late 
stage of PD, and produce one year-long therapeutic effects at an early stage of PD.
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1. Introduction
Parkinson’s disease (PD) is one of the fastest growing neurological disorders in the 
developed world that affects millions of people over 60 years of age [1]. The motor 
symptoms of PD result from the progressive loss of midbrain dopaminergic neurons that 
cause a decline in the levels of dopamine (DA) in the central nervous system (CNS), leading 
to severely impaired motor function. The existing therapeutic regimens provide only 
symptomatic relief to the patients and the treatments regimens are hindered by the 
development of drug resistance and progressive adverse side effects such as motor 
complications and dyskinesia [2]. For instance, in the case of L-DOPA, the current “gold 
standard” for PD treatment, patients typically respond well for several years, but then 
become unresponsive to therapy [3]. In addition, due to fast clearance, L-DOPA should be 
taken several times a day to sustain necessary DA levels in the brain.
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A growing body of evidence indicates the usefulness and efficacy of neurotrophic factors for 
the treatment of PD [4–17]. Glial cell line-derived neurotrophic factor (GDNF) is a founding 
member of the GDNF family of ligands (GFL) and has been shown to interact with GFRA2 
and GDNF family receptor alpha 1. Human GDNF (monomer) contains 135 aminoacidss 
residues, which is a disulfide-linked homodimer, and it shares 99% and 93% a.a. sequence 
identity with mouse and rat GDNF, respectively [18]. It is a small protein that was first 
identified as a potential therapeutic agent for PD based on its ability to promote the survival 
of embryonic DA neurons in vitro [4]. Later, intracranial infusions of GDNF were shown to 
provide protection and restoration of DA neurons in rodent [5–7] and primate [12, 14–17] 
models of PD. Furthermore, it was reported that bone marrow-derived stem cells, which 
were transduced ex vivo with lentivirus expressing GDNF gene and then transplanted into 
recipient mice dramatically ameliorated PD-related inflammation and neuronal degeneration 
resulting in axon regeneration and reversed hypoactivity in mice [19]. In addition, gene 
delivery systems for GDNF using adeno-associated viral vectors were suggested for the 
advanced PD patients (Clinical Trials ID: ) [20]. Finally, in a recent clinical trial, GDNF 
treatment was shown to produce promising therapeutic effects on damaged brain cells in PD 
patients. Forty-one participants underwent robot-assisted surgery to have four implanted 
tubes, which allowed GDNF to be infused directly to the affected brain areas with pinpoint 
accuracy [21]. Unfortunately, these brain infusions carry a high risk of adverse effects, and 
have poor patient adherence.
Herein, we propose to use genetically modified inflammatory response cells, for the delivery 
of therapeutics to the brain to treat PD. The chronic inflammation that is present in the PD 
brain [22] provides a rationale for the targeted drug delivery using such cells as monocytes 
and macrophages. This approach could offer several advantages over standard drug 
administration regimens, including targeted transport to local areas of disease where 
inflammatory processes are active, and sustained release of the therapeutic payload at the 
disease site. In this work, we evaluated whether the genetically modified autologous 
macrophages could reach the disease site and elicit therapeutic effects in transgenic mice 
with mild inflammation. We used Parkin Q311X(A) mice that represents Turkish early-onset 
PD directed to DA neurons of the Substantia Nigra pars compacta (SNpc) and the ventral 
tegmentum area (VTA) [23]. These mice have a truncated mutant parkin gene, whose 
expression is selectively driven in DA neurons [24]. This widely used animal model exhibits 
several key features of the disease in humans, such as a slow progressive course of 
phenotypic manifestations and neurodegeneration, adult-onset degeneration of nigrostriatal 
dopamine circuitry, and motor deficits.
We report here the development of new drug delivery systems for systemic administration 
neurotrophic factors using autologous macrophages. The specific advances to the field 
contributed by this body of work can be outlined in three main points. First, we 
demonstrated that intravenous injections of GDNF-macrophages were able to not only 
prevent and slow down neurodegeneration but also reverse the course of the disease in 
Parkin Q311X(A) mice with advanced stages and restore the already impaired locomotor 
functions to the levels observed in wild type animals. Second, the obtained data regarding 
biodistribution of autologous macrophages indicated that even mild brain inflammation 
manifested in transgenic mouse PD model attracted the cell-carriers to the brain and ensured 
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targeted GDNF delivery in Parkin Q311X(A) mice. Finally, prolonged sustained therapeutic 
effects were recorded in PD mice with early stages of the disease. Thus, ameliorated 
neuronal degeneration in SNpc, and improved the locomotor functions were recorded for 
nearly a year after the treatment.
2. Materials and Methods
2.1. Plasmids and Reagents
The gWIZ™ high expression vectors encoding the reporter gene luciferase (Luc) 
(gWIZ™Luc) under control of an optimized human cytomegalovirus (CMV) promoter 
followed by intron A from the CMV immediate-early (IE) gene were used throughout the 
study (Gene Therapy Systems, San Diego, CA). Human GDNF cDNA (NM_199234, 
Supplementary Figure S1 A) was provided by OriGene (Rockville, MD). The sequence for 
GDNF-encoding plasmid DNA (pDNA) can be found on web page: http://
www.origene.com/human_cdna/NM_199234/SC307906/GDNF.aspx. The GDNF-encoding 
plasmid under CMV promoter was expanded in DH5α E.coli and isolated using Qiagen 
endotoxin-free plasmid Giga-prep kits (Qiagen, Valencia, CA) according to the supplier’s 
protocol. The manufactured GDNF pDNA was then characterized by digestion with a single 
cut (AlwNI), and a double cut (AlwNI & PflMI) and run in 1% DNA electrophoresis gel 
(100V, 60 min) as shown on Supplementary Figure S1 B. The encoded human GDNF is a 
secreted protein with the leading sequence of the first five N-terminal amino acids: Met-Ser-
Pro-Asp-Lys. jPEI-macrophage reagent (jPEI) for transfection of primary macrophages was 
purchased from Polyplus Transfection Co. (New York, NY, USA). A lipophilic fluorescent 
dye, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindo-carbocyanine iodide (DIR), was purchased 
from Thermo Fisher Scientific (Waltham, MA, USA). Murine macrophage colony-
stimulating factor (MCSF) was purchased from Peprotech Inc (Rocky Hill, NJ).
2.2. Cells
Bone marrow-derived cells extracted from murine femurs (wild type littermates of Parkin 
Q311X(A) female mice, 2 mo. old) were seeded in T75 flask, and cultured for 10 days in the 
media supplemented with 1000 U/ml macrophage colony-stimulating factor (MCSF) to 
obtain primary bone-marrow macrophages (BMM) [25]. A few non-differentiated cells that 
do not attach to the flask was removed by washing. The purity of macrophages culture was 
determined by flow cytometry using FACSCalibur (BD Biosciences, San Jose, CA), and 
95% of cells were found to be CD11b+.
2.3. Animals
Two breeding pairs of Parkin Q311X(A) mice were purchased from the Jackson Laboratory 
(Bar Harbor, ME, USA) twelve weeks of age, and were treated in accordance to the 
Principles of Animal Care outlined by National Institutes of Health and approved by the 
Institutional Animal Care and Use Committee of the University of North Carolina at Chapel 
Hill. Several cohorts of transgenic mice as well as their wild type controls were bred in 
house. The genotyping of pups was carried by PCR analysis of Parkin Q311X(A) gene was 
performed for parents, a negative control wild mouse, and several mice generations 
according to manufacturers protocol (Supplementary Figure S2). Mice were housed in a 
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temperature and humidity controlled facility on a 12 h light/dark cycle and food and water 
were provided ad libitum.
2.4. Transfection of Macrophages
BMM were incubated with a mixture of Luc- or GFP-, or GDNF-encoding pDNA, and jPEI-
Mac or GenePORTER 3000 (GP3K) reagents in serum free media for four hours. 
Specifically, 14 μg pDNA was added to 2,040 μL diluent, and combined with 762 μL serum-
free media and 190 μL jPEI-Mac or GP3K. The obtained mixture was added to the cells 
grown on T75 flask (approximately 20 x106 cells/flask). Following incubation, an equal 
volume of full media containing 20% FBS was added bringing final serum concentration to 
10%. Additionally, macrophages were transfected by electroporation at various conditions. 
Briefly, 30x106 BMM were spanned down at 1000 RPM for 5 min, and then re-suspended in 
300 μL electroporation buffer (Neon Transfection system, Thermo Fisher Scientific) and 
supplemented with 30 μg Luc-pDNA. The aliquots of cell suspension with Luc-pDNA or 
GDNF-pDNA (10 μL) were placed into electroporation cell, and electroporated at various 
conditions according to manufacturer’s protocol. The electroporation conditions were as 
follows: #1 (voltage 0; width 1; pulses 1); #2 (voltage 1300; width 20; pulses 2); #3 (voltage 
1700; width 20; pulses 2); #4 (voltage 1400; width 20; Pulses 2). Then, the cells were 
supplemented with 500 μL antibiotic-free media and cultured for various time points. The 
luciferase activity or percentage of transfected macrophages, or GDNF levels in the cells and 
cell media were assessed by luminescence or FACS, or ELISA, respectively. For measures 
of the overexpressed GDNF release, culture media from transfected macrophages was 
collected at various time points, and assessed for the levels of GDNF by ELISA. The 
number of GFP-transfected macrophages and the expression levels in relative fluorescent 
units (RFU) were assessed by FACS as described earlier [26].
2.5. Confocal Microscopy
Studies were carried out to determine expression of the reporter gene (GFP) in transfected 
macrophages as described earlier [26]. GFP expression in primary macrophages was 
visualized by a confocal fluorescence microscopic system ACAS-570 (Meridian 
Instruments, Okimos, MI, USA) with argon ion laser (excitation wavelength, 488 nm) and 
corresponding filter set. Digital images were obtained using the CCD camera (Photometries) 
and Adobe Photoshop software. To visualize effects of GDNF-transfected macrophages on 
neuronal differentiation, PC12 neuronal cells were transduced with lentiviral vector 
encoding mCherry as well as a puromycin resistance gene. Then, macrophages were 
transfected with GDNF-encoding pDNA as described above, the media from GDNF-
macrophages was collected and added to non-differentiated mChery-PC 12 cells for 72 h. 
mCherry-PC12 cells incubated with serum-free media or cell media from sham-transfected 
macrophages (i.e. cells transfected with GFP-encoding pDNA) were used as controls.
2.6. Immunohistochemical and Stereological Analyses
For the assessment of neuroprotective effects, tyrosine hydroxylase staining was used to 
quantitate numbers of dopaminergic neurons [27]. For the detection of microglial activation, 
tissue sections were incubated with primary monoclonal rat anti mouse Mac1 antibodies 
(AbD Serotec, Raleigh, NC, USA), and secondary biotinylated goat anti-rat antibodies 
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(Vector Laboratories, Burlingame, CA, USA). For the assessment of the formation of 
proteinase K-resistant α-synuclein, the brain tissue slices were incubated with 0.3% Triton 
X-100 in PBS for 20 min, washed and incubated with 10ug/mL proteinase K in PBS for 10 
min to clear tissues from non-aggregated α-synuclein. Then, slides were incubated with 
primary antibody anti-α-synyclein (Abcam ab131508, 1:100 dilution) for 48 h at 4°C, 
washed with 3x PBS, and secondary antibody goat anti-rabbit IgG H+L (Alexa Flour 488, 
Invitrogen A-11008) for 1 h at RT in the dark. Levels of astrocyte activation were 
determined in the ventral midbrain region by fluorescent analysis of GFAP expression with 
primary antibody anti-GFAP (Abcam ab7260, 1:500 dilution), and secondary antibody goat 
anti-rabbit IgG H+L (Alexa Flour 488, Invitrogen A-11008) for 1 h at RT in the dark. The 
total number of TH-positive SN neurons, MAC1-positive microglial cells were counted 
using the optical fractionator module in StereoInvestigator software (MicroBrightField, Inc., 
Williston, VT, USA) [28]. Quantification of the fluorescence levels of α-synuclein and 
astrocytes was performed as the function of the positive area by ImageJ software for mean 
Fluorescent Intensity (MFI) and % Area of fluorescence (free access provided by National 
Institute of Health). Briefly, Region of Interest (ROI) was selected on each slide and 
fluorescence intensity was measured by the Image J measuring tool. Background was 
calculated by measuring mean fluorescence level of an area with no cells, and subtracted 
from Raw Image data (N = 15).
Hematoxylin and eosin (H&E) staining: Brain tissues were cut into sections of 10 
micron thickness and stained with H&E. Briefly, sections were rewarmed at room 
temperature for 30 minutes, then exposed to xylene and re-hydrated with 100% ethanol, 95 
and 70% ethanol, followed by staining with hematoxylin dye for 15 min, prior to washing 
with distilled water. Subsequently, tissue sections were stained with eosin for 20 sec, 
dehydrated with gradient ethanol after washing with tap water, and tissues were then cleared 
by xylene and mounted using mounting media for visualization. Images were analyzed using 
a Zeiss (Germany) inverted fluorescence microscope with a 560 Axiovision camera at 5x, 
20x and 40x.
Nissl staining: Brain sections of 10-micron thickness were stained with cresyl violet 
acetate solution (Nissl). Briefly, sections were rewarmed at room temperature for 30 
minutes, then exposed to xylene and immersed in 100% ethanol, 95%, 75% ethanol and 
distilled water, and then stained with a cresyl violet solution for 20 minutes. Sections were 
washed in distilled water, immersed in 75% ethanol, 95% and 100% ethanol. Tissues were 
then cleared by xylene and mounted using mounting media for visualization. Images were 
analyzed using a Zeiss (Germany) inverted fluorescence microscope with a 560 Axiovision 
camera at 5x, 20x and 40x.
2.7. Bioimaging and Infrared Spectroscopy (IVIS)
To track systemically injected cell-carriers in the PD mice, macrophages were labeled using 
three different methods. First, primary macrophages were labeled with DIR lipophilic dye 
(Invitrogen, Carlsbad, CA, USA) according to manufacturer’s protocol. Briefly, BMM (1 x 
106 cell/mL) were incubated with 7 μM DIR in PBS for 20 min at 37C. Followed incubation, 
the cells were spin down and washed 3x with ice-cold PBS, and re-suspended in saline. 
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Finally, primary macrophages were labeled with Celsense (Celsense, Inc., Pittsburg, PA, 
USA) that is a fluorocarbon-based emulsion engineered to safely label cells ex vivo without 
use of transfection regents. Briefly, macrophages (4 x 106 cell/mL) were incubated with 
Celsence in complete media (1.5 mg/ml) for 18 h, and rinsed 3x times with ice-cold PBS. In 
addition, autologous macrophages were transfected with Luc-encoding pDNA using GP3K 
transfection reagent as described earlier [29]. In a parallel experiment, Parkin Q311X(A) 
mice (4 mo. of age) and their wild type littermates were injected with DIR-labeled BMM, or 
Celsense-labeled BMM, or Luc-expressing macrophages (2 x 106 cell/100 μL/mouse) via 
the intratail vein (i.v.), and animals were imaged by Xenogen IVIS Optical Imaging System. 
At the end point, animals were sacrificed and perfused as described earlier [30], main organs 
were removed, washed, post-fixed in 10% phosphate-buffered paraformaldehyde, and 
evaluated by IVIS Aura software (Spectral Instrument Imaging, Tucson, AZ, USA).
2.8. Behavioral Tests
For the traditional constant speed Rotarod test, mice were trained and tested as previously 
described with slight modifications [31]. Parkin Q311X(A) mice (4 mo. old) were i.v. 
injected with autologous GDNF-macrophages transfected with GDNF-encoding pDNA, or 
sham macrophages, or saline (once a week, 3x weeks, 2x106 cells/100μL/mouse). WT mice 
injected with saline were used as a control. GDNF-macrophages were obtained using 
transfection agent as described above and cultured 24 h prior to the administration. Animals 
were treated once a week for three weeks at 4 mo. (early stage) or 16 mo. (late stage of the 
disease). Then, the animals were subjected to standard behavioral tests; Wire hanging test, 
and accelerating Rotarod procedure, and Escaping activity test were performed as described 
in [29] before the treatment and later on.
2.9. Statistical Analysis
For the all experiments, data are presented as the mean ± SEM. For analysis of statistical 
significance of therapeutic effects assessed by behavioral tests and immuniohistochemistry, 
the difference between scores at baseline and endpoint were compared by group (PD mice 
injected with GDNF-macrophages, sham macrophages, or saline, as well as WT mice 
injected with saline). For all three tests the baseline was mo. 4. The immunohistochemical 
and stereological outcomes were also compared by the same four groups using the values at 
16 mo, when the mice were sacrificed. A one-way ANOVA was used to see if there were any 
significant differences between groups. If the differences between the groups were 
significant at the 0.05 level after a using the Holm method for to control the family wise 
error rate for the nine different outcomes that were tested using a one-way ANOVA. Then 
pairwise tests were conducted using a Bonferroni correction. Because pairwise comparisons 
for each outcome were only done if the one-way ANOVA was found to be significant, 
multiple comparisons for the pairwise testing only controlled for the number of pairwise 
comparisons for the given outcome, not the number of possible pairwise comparisons for all 
outcomes.
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3.1. Transfection of Primary Macrophages with pDNA Encoding Reporter and Therapeutic 
Genes
As part of our strategy, efficient transfection of primary macrophages with pDNA encoding 
reporter or therapeutic genes is crucial. We acquired two different methods for transfection 
of primary autologous macrophages including macrophage transfection agent (jPEI) (Figure 
1), and the electroporation method (Supplementary Figure S3). Successful transfection of 
primary bone marrow-derived macrophages (BMM) was accomplished with pDNA 
encoding green fluorescence protein (GFP) (Figure 1 A, B), luciferase (Luc) (Figure 1 C), 
and GDNF (Figure 1 D). The optimal conditions for experiments utilized earlier [26] 
provided high levels and duration of the encoded proteins expression. For example, up to 
30% cells expressed the reporter protein GFP at day 3 (Figure 1 A). Of note, as GDNF is a 
secreted molecule, a significant amount of GDNF was detected in the transfected cells, as 
well as in cell culture media (Figure 1D), but not in macrophages transfected with sham 
vector (dashed line). Successful transfection with GFP-encoding pDNA was also confirmed 
by confocal microscopy at day 3 (Figure 1 B).
Next, efficient transfection of BMM was also accomplished using electroporation 
(Supplementary Figure S3). Different electroporation conditions #1 - #4 that express 
different voltage and pulse (described in Experimental Section) were utilized to optimize the 
transfection efficiency with the reporter pDNA (Supplementary Figure S3 A). The peak level 
of GDNF in primary macrophages transfected by electroporation was at day 1 
(Supplementary Figure S3 B), although the GDNF levels in the cell media were still high at 
days 4 and 7 with the optimal condition # 4. Confocal images at day 3 confirmed expression 
of GFP in transfected cells (Supplementary Figure S3 C).
Finally, a profound effect of GDNF released from pre-transfected macrophages in vitro was 
demonstrated in PC12 neuronal cells that are known to express GDNF receptors. To 
visualize cells by confocal microscopy, PC12 neuronal cells transduced with a lentiviral 
vector encoding mCherry (red) were utilized. Macrophages were transfected with GDNF-
encoding pDNA with the transfection agent as described above, and conditioned media was 
collected after 72 h. Non-differentiated mCherry-PC12 cells were supplemented with media 
from GDNF-transfected or control sham-transfected macrophages, the cells were cultured 
for 72 h, and visualized by confocal microscopy (Supplementary Figure S4). Confocal 
images revealed a pronounced outgrowth of axons and dendrites in neuronal PC12 cells 
cultured with conditioned media from GDNF-macrophages (Supplementary Figure S4 B) 
compared to control non-differentiated cells cultured in serum-free media (Supplementary 
Figure S4 A). No effect on axonal growth was observed in neuronal cells supplemented with 
media from sham-transfected macrophages (Supplementary Figure S4 C).
3.2. Systemically Injected Macrophages Migrate to Inflamed Brain Tissues in Parkin 
Q311X(A) Mice
To prove the ability of macrophages to target inflamed brain tissues, the cell-carriers were 
labeled using three different methods: (i) labeling of lipids of macrophages with 
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hydrophobic DIR dye, or (ii) loading of macrophages with fluorocarbon formulation 
Celsense, or (iii) transfection of macrophages with Luc-encoding pDNA to express Luc. 
First, kinetics of the appearance of systemically injected macrophages in PD mouse brain at 
early stage of disease (4 mo. of age) and accumulation in peripheral organs was examined 
with DIR labeled BMM (6x106 cells/100 μL/mouse, N = 4) (Figure 2 A, D). Of note, no 
aggregation of the cell-carriers in the treatment solution was recorded. The same age-
matched wild type (WT) mice were used as controls (Figure 2 B, E). Considerable DIR 
fluorescence was detected in the PD brain as early as 4 h after i.v. administration of DIR-
macrophages, and leveled off after 24 h (Figure 2 A, C). In contrast, significantly lower 
levels of macrophages were registered in the brains of healthy WT animals (Figure 2 B, C). 
The quantification of levels of fluorescence in the brain of living animals (Figure 2 C), as 
well as the images of postmortem main organs collected from perfused mice at the end point 
(Figure 2 D, E) confirmed this observation. We suggest that this effect is due to the ability of 
macrophages home to regions of inflammation and neurodegeneration, traveling via the 
gradient of inflammatory signals, chemokines and cytokines. Of note, the perfusion 
procedure allowed assessment of macrophages in the organ tissues avoiding possible 
contamination by these cell-carriers in the blood stream. Furthermore, low fluorescent 
signals at the first hour on dorsal images might indicate that most DIR-macrophages were 
circulated in the blood stream and accumulated in main excretion organs, liver, lungs, and 
kidney, as seen on Supplementary Figure S5.
Next, the accumulation of macrophages in PD mouse brain at 6 h after the i.v. injection was 
confirmed with macrophages labeled with Celsense, a dye that enable real-time tracing of 
cell-based therapeutics in animals (Figure 2 F, G). The results showed relatively high 
accumulation of cell-carriers in the lungs, liver, spleen, with lower but detectable levels in 
the kidney and brain. Notably, macrophages accumulated significant amount of Celsense 
with almost no toxicity observed at these conditions (Supplementary Figure S6).
Finally, macrophages were transfected with pDNA encoding luciferase (Luc) using 
transfection reagent as described above. This approach allowed tracing macrophages 
expressing the encoded protein Luc. PD mice were systemically injected with Luc-
macrophages and examined by the IVIS imaging system 4 h after the injection (Figure 2 H). 
The images revealed a considerable amount of luminescence in the inflamed brain of 
transgenic PD mice, but not in brains of the healthy WT animals. Of note, along with the 
greater brain uptake, there was markedly greater systemic uptake of Luc-macrophages in PD 
mice compared to WT animals (Figure 2 H). This consistent with our earlier reports 
regarding PD mice with acute brain inflammation induced by i.c. injections of 6-OHDA 
[26], or LPS [30], suggesting that systemically administered macrophages migrate to sites of 
inflammation and accumulate in the brain of PD mice. Overall, the results from all three 
experiments corroborated with each other and collectively suggested that a significant 
amount of systemically administered autologous macrophages were able to reach the brain 
in Parkin Q311X(A) mice.
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3.3. GDNF-macrophages Restore Motor Functions in Parkin Q311X(A) Mice with Severe 
Late-stage of PD
Massive striatal DA deficiency causes detectable locomotor deficits in Parkin Q311X(A) 
transgenic mice. These deficits can be used to assess therapeutic effect of GDNF-
macrophages. First, Parkin Q311X(A) transgenic mice at severe late stage of the disease (16 
mo. of age) were systemically injected with GDNF-macrophages, or sham macrophages, or 
saline. WT mice injected with saline were used as a control. Animals were treated once a 
week for three weeks. To assess changes in the animal motor functions over time, all groups 
were subjected to a battery of behavioral tests, including: Wire hanging test, and Rotarod 
test. The null point was established for all groups at 16 mo. immediately before treatment 
onset.
Systemic administration of GDNF-macrophages at this late severe stage of the disease 
improved locomotor activity of PD mice (Supplementary Video S1) compared to those 
injected with saline (Supplementary Video S2). The results of Wire hanging test (Figure 3 
A) and Rotarod test (Figure 3 B) revealed significant (Supplementary Tables S1 and S2) 
increases in remaining time for PD mice treated with GDNF-macrophages up to the levels of 
healthy WT littermates.
3.4. Long-term Sustained Effects of GDNF-macrophages on Motor Functions in Parkin 
Q311X(A) Mice Treated at Early-stage of PD
All behavioral tests, including Wire Hanging test, Rotarod test, and Escaping Activity test 
demonstrated statistically significant preservation of locomotor functions in PD mice treated 
with GDNF-macrophages (Figure 4). Specifically, systemic administration of GDNF-
macrophages significantly increased remaining time in Wire hanging and Rotarod tests 
(Figure 4 A and B, respectively), and reduced escaping time (Figure 4 C) to the levels 
observed in healthy WT animals. In particular, using one-way ANOVA test gave a p-value of 
8.87 × 10−3, indicating that there is a difference between the groups in average time for the 
Wire hanging test (Supplementary Table S3). The Bonferroni corrected p-value for the 
pairwise t-test for each pair of groups indicated that the Parkin Q311X(A) mice treated with 
GDNF-macrophages have significantly higher retention times than those treated with sham-
transfected macrophages, or treated with saline (Supplementary Table S4). This signifies that 
systemic administration of GDNF-macrophages resulted in the preservation of locomotor 
activity in PD mice. Similar to Wire hanging test scores, the statistical analysis for the 
Rotarod test by one-way ANOVA gave a p-value of 3.62 x 10−5, suggesting that there was a 
significant improvement in the remaining time on rotarod for PD mice treated with GDNF-
macrophages (Supplementary Tables S5 and S6). Lastly, the escaping activity test also 
showed qualitative improvement in the escaping time for PD mice treated with GDNF-
macrophages, although the differences were not statistically significant (Supplementary 
Table S7).
3.5. Neuroprotective Effect of GDNF-macrophages in Parkin Q311X(A) Mice
At the endpoint of the experiment described above, 16 mo. old animals were sacrificed; 
postmortem brains were harvested and sectioned using a microtome. The mid-brain slides 
were stained for the expression of tyrosine hydroxylase (TH), a marker for DA neurons 
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(Figure 5 A–D). The quantitative assessment of the number of DA neurons is shown on 
Figure 5 E. The brain slides of PD mice showed complete degeneration of DA neurons in the 
SNpc (Figure 5 A, E) compared to healthy WT mice (Figure 5 D, E). In contrast, systemic 
administration of GDNF-macrophages dramatically ameliorated PD-related 
neurodegeneration (Figure 5 B, E) compared to the PD animals treated with saline (Figure 5 
A, E). The p-value for the one-way ANOVA was 0.02, which is significant at the 0.05 level 
indicating at least one difference between the groups in the number of neurons 
(Supplementary Table S8). Of note, no statistically significant difference was found between 
PD mice treated with GDNF-macrophages and healthy WT littermates (Supplementary 
Table S9). This suggests a near complete abrogation of neurodegeneration process in PD 
mice treated with GDNF-macrophages. Sham-transfected macrophages showed a subtle 
neuroprotective effect (Figure 5 C, E) that was much less than that in GDNF-macrophages 
treatment groups. The observed intrinsic biological activity of sham macrophages may be 
due to a particular subset of M2 cell-carriers differentiated with MCSF [26] that show mild 
neuroprotective effects by themselves. Additional images shown in Supplementary Figure 
S7.
The neuropathology of PD includes brain inflammation, microglial activation, and secretion 
of neurotoxins, all of which contribute to neurodegeneration and degradation of motor 
functions [32]. Therefore, we assessed the effect of GDNF-macrophages on microglial 
activation in PD mice. The neurodegeneration in 16 mo. of age PD mice treated with saline 
was accompanied with substantial brain inflammation as displayed by up-regulated 
expression of MAC1 by microglia within the SNpc that exhibited a more amoeboid 
morphology (Figure 6 A, E) than ramified microglia in saline-treated WT mice (Figure 6 D, 
E). Thus, postmortem brains of PD mice treated with saline showed significant higher 
number of activated microglia when compared to brains from WT mice (Supplementary 
Tables S10 and S11). In contrast, a potent anti-inflammatory effect of GDNF-macrophages 
was demonstrated in PD mice (Figure 6 B, E) compared to PD mice treated with saline 
(Figure 6 A, E) that was confirmed by reduction in microgliosis as measured by MAC1 
expression using one-way ANOVA and Bonferroni test (Supplementary Tables S10 and 
S11). Of note, treatment with sham-transfected macrophages produced a mild anti-
inflammatory effect in PD mice (Figure 6 C, E). Additional images shown in Supplementary 
Figure S8.
Next, systemic administration of GDNF-macrophages significantly (Supplementary Tables 
S12 and S13) decreased astrocytosis in PD mice (Figure 6 G, K) compared to healthy wild 
type mice (Figure 6 J, K). No effect of sham-transfected macrophages (Figure 6 H, K) was 
observed in PD mice. Additional images are shown on Supplementary Figure S9. Overall, 
the effect on astrocytosis is consistent with decreases of microglial activation in PD mouse 
brain upon GDNF-macrophages treatment suggesting significant inhibition of the neuro-
inflammation process.
An etiological factor, α-synuclein, is known to accumulate in SNpc, as well as other brain 
regions in PD patients [33, 34]. The effect of GDNF-macrophages on accumulation of 
proteinase K-resistant α-synuclein was examined using brain slides from PD mice at 16 mo. 
of age (Figure 7). Proteinase K treatment of brain slides from WT mice almost completely 
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destroyed α-synuclein immunohistochemistry staining (Figure 7 D, E), while α-synuclein 
positive neurons were abundantly detected in cells located in the SNpc of PD mice (Figure 7 
A, E). Importantly, PD mice treated with GDNF-macrophages (Figures 7 B, E) showed a 
significantly lower number of proteinase K-resistant α-synuclein (Supplementary Tables 
S14 and S15) compared to other PD animal groups. Interestingly, there was also substantial 
reduction of proteinase K-resistant α-synuclein in the SNpc of PD mice treated with sham 
transfected macrophages (Figure 7 C, E). We also attribute this effect to mild 
neuroprotective effects of M2 macrophages. Additional images shown on Supplementary 
Figure S10. Of note, no total weight loss was recorded in PD mice injected with either 
GDNF-transfected or sham-transfected macrophages (Supplementary Figure S11). This 
signifies absence of general toxicity of the cell-based formulations upon multiple 
administrations of macrophage treatments.
Finally, the expression analysis and histological stain by Nissl (Figure 8) revealed a normal 
distribution of neurons (N) with minimal loss of cell bodies in the SNpc of WT mice (4 mo). 
Tissue showed neurons with both pyramidal and non-pyramidal shape and integrative and 
well maintained morphology. Some characteristics analysis showed extension of the Nissl 
substance (chromatic substance) into the base of each dendrite (D) but not into the axon 
hillock that gives rise to the axon (A). The nucleus was visible inside ells with no apparent 
presence of Nissl-positive chromatin clumps. Presence of glial nuclei (G) and astrocytes 
(As) were also evident. In contrast, tissues from 4 mo. old PD mice showed lower number of 
Nissl bodies with fewer numbers of neurons, glial nuclei and astrocytes present, when 
compared with the 4 mo. old WT mice tissues. In general, all brain tissues removed post-
mortem from old mice showed reduced number of cells in comparison to brain tissues from 
young mice. In the case of the control old WT mice, lower number of Nissl bodies were 
detected. Despite the lower presence of Nissl bodies, neurons morphology and the number 
of glial cells present were similar to brain tissues from old mice. Of note, the brain tissues 
from PD mice treated with saline at 16 mo. of age showed presence of large sized neuronal 
cells with detectable loss of dendrites and axons, and neuron vacuolation (Figure 8). In 
contrast, tissues from PD mice treated with the GDNF-macrophages showed better tissue 
integrity; the neurons appeared healthier with normal morphology and minimal sign of 
neuronal vacuolation. Finally, tissues from PD mice treated with sham macrophages at 16 
mo. showed both flat elongated and dopaminergic neurons.
H&E staining of the brain slides of PD mice at late stages of the disease confirmed the 
protection of neuronal cells in SNpc by systemic administration of GDNF-macrophages 
(Supplementary Figure S12). Microscopic appearance of the substantia nigra stained with 
H&E showed normal cell morphology with minimal vacuolation in brain tissues removed 
post-mortem from 4 mo. old WT mice and in brain tissues removed post-mortem from 4 mo. 
old PD mice. In contrast, brain tissues from WT mice or PD mice that were treated with 
saline at 16 mo. of age showed signs of disruption and vacuolation. Of note, only groups 
from PD mice treated with the GDNF-macrophages at 16 mo. of age showed higher 
integrity, with no visible sign of aberrant morphology of neurons.
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Cell therapy for PD patients is an innovative promising approach that may be a key for true 
neuroregeneration and reverse of the disease progression [35]. Early studies utilized 
transplantation of fetal nigral DA neurons and autologous DA-secreting cells was first 
utilized to preserve host neurons and supply brain tissues with DA [36, 37]. Later, allogeneic 
bone marrow-derived mesenchymal stem cells (MSCs) [19, 38], embryonic stem cells 
(ESCs) [39], and neural stem cells NSCs [40, 41] were used to support/induce damaged DA 
neurons in animal PD models. Finally, human induced pluripotent stem cells (iPSCs) were 
shown to protect neurons after cerebral transplantation [42]. In 2016, the first approved 
clinical trial using iPSCs to treat PD patients was started in Melbourne, Australia, by the 
International Stem Cell Corporation [43]. Cell-based interventions showed strong 
therapeutic effects upon intracranial transplantations that was utilized in most of these 
studies. Unfortunately, surgery requires relatively invasive maneuvers and involves 
expensive medical care. Furthermore, a risk of immune rejection, and possibility for tumor 
formation are among disadvantages of these cell-based therapeutic options [44].
A long-term objective of these investigations is to develop targeted cell-mediated drug 
delivery system for therapeutic proteins to the brain using autologous macrophages. We 
demonstrated here that genetically modified macrophages can reach the brain in Parkin 
Q311X(A) mice upon systemic administration and produce potent long-term therapeutic 
effects. To take advantage of the ability of macrophages to deliver therapeutic proteins to the 
inflamed brain, primary macrophages should be efficiently transfected with therapeutic 
pDNA, which is not a simple task. We verified several approaches for transfection of 
primary macrophages including using specific jPEI-macrophage reagent (jPEI) and 
electroporation method. The obtained results indicated that efficient transfection of primary 
macrophages were achieved with reporter (Luc, or GFP) and therapeutic (GDNF) pDNA ex 
vivo using both jPEI transfection reagent and electroporation methods. Moreover, media 
collected from GDNF-macrophages promoted axonal outgrowth in PC 12 neuronal cells in 
vitro. This signifies that GDNF was released from pre-transfected macrophages in active 
form. Of note, we demonstrated earlier [26, 45–48] that GDNF-macrophages are secreting 
extracellular vesicles (EVs), packed with therapeutic protein-encoding genetic material 
(pDNA and mRNA), active GDNF, and NF-κb, a transcription factor involved in the 
encoded gene expression. This mechanism may play a significant role in efficient 
preservation of neurons against degradation [26]. In addition, the membranotropic properties 
of GDNF-carrying EVs may facilitate GDNF binding to GFRα-1 receptors expressed on DA 
neurons [18].
These investigations were carried out in a transgenic PD mouse model that manifests in slow 
developing neurodegeneration upon mild inflammation and accumulation of α-synuclein 
deposits in the mid brain. One of the most important findings of this work is that GDNF-
macrophages injections were able to not only prevent the neurodegeneration in PD mice that 
were treated at mild early-stages of the disease, but also restore the functions of neurons in 
mice with already developed neurodegeneration at late severe-stages of the disease. Thus, 
systemically administered GDNF-expressing macrophages migrated to sites of brain 
inflammation, accumulated in the brain of transgenic mice and provide potent 
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neuroprotection that is consistent with our previously reported findings for toxin-induced 
disease models with acute brain inflammation [26, 28, 46, 47, 49, 50]. Of note, accumulation 
of Luc-macrophages in the brain of PD mice was greater than in their wild type 
counterparts. These findings are of great importance considering mild neurodegeneration 
and neuroinflammation process in PD patients.
The treatments resulted in significant improvement in locomotor activity in PD mice that 
was signified in increased remaining time in Wire hanging and Rotarod tests, and reduced 
escaping time for transgenic PD mice. The second important finding is that GDNF-
macrophages provided long-term effect on motor functions for more than a year. This 
suggests that future Parkinson’s patients potentially might need receiving treatment only 
once a year, or even longer, that is very important for this chronic disease. GDNF delivered 
to the PD brain has direct effects on neuronal integrity that in turn resulted in reduction of 
astrocytosis and microgliosis. No significant effects were observed in PD mice treated with 
sham-transfected macrophages, although some tendency for increased neuron survival, and 
decreased in proteinase K-resistant α-synclein, as well as improved motor functions in these 
mice by sham-macrophages were recorded. This later effect may be attributed to anti-
inflammatory subtype of M2 macrophages utilized in these studies. We reported similar 
effects in PD mice with acute inflammation earlier [26, 48]. Importantly, systemically-
administered M2 macrophages home brain tissues, and sustained their phenotype in PD 
mouse models. Finally, contrary to toxin-induced conditions, PD patients do not have a high 
inflammation levels in the brain. Therefore, the note that even mild inflammation process in 
transgenic mice at early stages of the disease promoted brain accumulation of systemically 
injected cell-carriers is significant regarding possible targeting of therapeutic proteins to the 
brain in PD patients.
The long-term sustained therapeutic effect of adoptively transferred GDNF-macrophages 
was observed for a duration of 12 months after the treatment in ParkinQ311(X)A mice. We 
suggested that the mechanism of this therapeutic intervention is more complex than a simple 
GDNF delivery by genetically-modified cell-carriers. We hypothesized that GDNF-
macrophages accomplished horizontal gene transfer to surrounding brain tissues as well. In 
this respect, we reported earlier that systemic administration of macrophages transfected ex 
vivo with a plasmid DNA (pDNA) encoding a potent antioxidant enzyme, catalase, produced 
months-long expression levels of catalase in the brain resulting in three-fold reductions in 
inflammation and complete neuroprotection in different mouse models of PD [26]. As a 
result, the single systemic administration of catalase-transfected macrophages significantly 
improved motor functions in PD mice.
Mechanistic studies revealed that transfected macrophages secreted extracellular vesicles, 
exosomes, packed with catalase genetic material, pDNA and mRNA, active catalase, and 
NF-κb, a transcription factor involved in the encoded gene expression. Exosomes efficiently 
transferred their contents to contiguous neurons resulting in de novo protein synthesis in 
target cells. Therefore, genetically modified macrophages serve as a highly efficient system 
for reproduction, packaging, and targeted gene and drug delivery to treat inflammatory and 
neurodegenerative disorders. Furthermore, horizontal gene transfer from macrophages to 
neuronal cells was confirmed based on different kinetics of gene expression in macrophages 
Zhao et al. Page 14













and target PC12 neuronal cells in vitro. The co-culture of these cells displays a delayed GFP 
expression profile with the highest levels shifted to day 8–12, while a pick of GFP 
expression in macrophages alone is on day 4 [26]. Next, we also demonstrated that 
macrophages that were pre-transfected with pDNA under tissue-specific Desmin promoter 
(muscles) pass the transgene to Desmin-positive myotubes, but not to Desmin-negative 
myoblasts [51]. Thus, the transferred gene is subsequently expressed in the acceptor cells, 
even if it is not transcribed in the initial cell-carriers, macrophages. Finally, we showed that 
macrophages can transfer exogenously introduced siRNA to surrounding cancer cells into 
solid tumors [52]. Thus, the knockdown of GFP expression in the human triple negative 
breast cancer (TNBC) MDA-231-GFP cells was demonstrated by IC21 macrophages loaded 
with GFP-siRNA via horizontal transfer of GFP-siRNA. Additionally, the delivery of 
therapeutic CIB1 -siRNA to MDA-MB-468 cells was confirmed in orthotopic solids in nude 
mice [52]. Overall, we concluded that the observed in this study sustained therapeutic effects 
of GDNF-macrophages are likely due to the horizontal gene transfer via GDNF-
macrophages, transfection of brain tissue and prolonged expression of GDNF in the brain. 
Ongoing studies in our lab are investigating more closely the mechanism of therapeutic 
effects by GDNF-transfected macrophages and the potential reversal of degeneration 
processes in the PD brain.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Macrophages were modified to produce glial cell line-derived neurotrophic 
factor
• Macrophages expressing neurotrophic factor reach brain in Parkinson’s 
disease mice
• GDNF-macrophages restore motor functions in transgenic mice at late stages 
of PD
• GDNF-macrophages produce one year-long therapeutic effects at early stages 
of PD
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Figure 1. Transfection of primary murine macrophages with pDNA-encoding reporter and 
therapeutic genes.
Transfections of macrophages with GFP- (A, B), or luciferase- (C), or GDNF-encoding 
pDNA (D) were carried out using jPEI-Mac reagent as described in Experimental section. 
Cells were washed and cultured in complete media for up to 7 days. The percentage of GFP-
transfected macrophages (A), or luciferase activity at day 3 (C), or GDNF levels in cells 
(black bars) or conditioned media (white bars) (D) were accessed by FACS (A), or 
luminescence (C), or ELISA (D), and visualized by confocal microscopy at day 3 (B). The 
bar: 50 μm. *p < 0.05, compared to sham-transfected macrophages (dashed line).
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Figure 2. Accumulation of autologous macrophages in the brain in PD mice.
Parkin Q311(X)A mice (4 mo. of age) were i.v. injected with 6x106 DIR-macrophages (A), 
or Celsense-macrophages (F), or Luc-transfected macrophages (H) and imaged by IVIS. 
WT mice were used as healthy controls (B, E, H). At the end point (72 h) mice were 
sacrificed, perfused, main organs were removed, and images by IVIS for PD mice (D, G), 
and WT mice (E). Fluorescence intensity in the brain area on IVIS images (A, B) was 
quantified and plotted vs. time (C) for PD mice (black circles), and WT mice (white circles). 
Systemically-administered macrophages reached the brain in PD mice at significantly 
greater levels than in WT mice (C). Imaging living animals injected with Luc-macrophages 
(H) and isolated organs (i.e. liver (1), lungs (2), spleen (3), kidney (4), and brain (5) of mice 
injected with Celsense-macrophages (F), as well as quantification of Celsense-macrophages 
levels in these organs (G) confirmed this result. Significant amount of macrophages reach 
PD mouse brain (G, red bar). Values are means ± SEM (N = 4 for all experiments), *p < 
0.05 compared to WT mice.
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Figure 3. Behavioral tests demonstrating restoration of locomotor functions in Parkin Q311X(A) 
mice upon treatment with GDNF-macrophages at late stages of disease.
Transgenic mice (16 mo. old) were i.v. injected with GDNF-transfected macrophages (2x106 
cells/100μL/mouse, once a week, 3x weeks, green), or saline (red), or sham macrophages 
(purple) once a week, 3x weeks. Wild type mice were systemically injected with saline 
(black). Wire hanging test (A), and Rotarod test (B) demonstrated significant improvements 
in motor functions upon treatment with GDNF-macrophages. Values are means ± SEM (N = 
6), *p < 0.05 compared to WT healthy mice. For detailed statistical comparisons, see 
Supplementary Tables S1 – S2.
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Figure 4. Behavioral tests demonstrating preservation of locomotor functions in Parkin Q311(X) 
mice upon their treatment with GDNF-macrophages at early stages of disease.
Transgenic mice (4 mo. old) were i.v. injected with GDNF-transfected (green), sham-
transfected macrophages (purple), or saline (red) (once a week x 3 weeks, 2x106 cells/
100μL/mouse, red arrows). WT mice were i.v. injected with saline (black). Wire hanging test 
(A), Rotarod test (B), and Escaping activity test (C) demonstrated significant improvements 
in motor functions upon treatment with GDNF-macrophages. Values are means ± SEM (N = 
6), *p < 0.05, **p < 0.005 compared to WT healthy mice. For detailed statistical 
comparisons, see Supplementary Tables S3–S7.
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Figure 5. GDNF-BMM protect dopaminergic neurons in Parkin Q311(X)A mice.
Transgenic mice (4 mo. old) were i.v. injected with PBS (A), or GDNF-transfected (B), or 
sham-transfected (C) macrophages (2x106 cells/100 μL/mouse) weekly 3x times. Wild type 
mice were systemically injected with PBS (D). Animals were sacrificed at mo 16, and brain 
slides were stained with TH, a marker for dopaminergic neurons. The obtained confocal 
images and quantification of TH+ neurons (E) indicate significant increases in neuronal 
survival in Parkin Q311(X)A mice upon GDNF-BMM treatment (B) compared to PD mice 
treated with saline (A). The administration of PD/sham BMM (C) also increased number of 
dopaminergic neurons in PD mice although at lesser extent than GDNF-transfected 
macrophages. The bar: 1 mm. Values are means ± SEM (N = 6), and *p < 0.05.
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Figure 6. GDNF-macrophages reduce neuro-inflammation in Parkin Q311X(A) mice.
Transgenic mice (4 mo. old) were i.v. injected with saline (A, F), or GDNF-macrophages (B, 
G), or sham-transfected macrophages (C, H) (2x106 cells/100 μL/mouse, once a week, 3x 
weeks). WT mice were systemically injected with saline (D, J). Animals were sacrificed at 
mo. 16, and brain slides were stained with Mac1 (A – D), a marker for activated microglia; 
or Ab to GFAP (F – J), a marker for activated astrocytes. Insets on the right lower corner are 
higher-power view of the SNpc area. The obtained bright field (A – D) and confocal (F – J) 
images, and quantification of activated microglial cells (E) and activated astrocytes (K) 
determined as the function of the positive area by ImageJ software for mean Fluorescent 
Intensity (MFI) and % Area of fluorescence, indicate significant decreases 
neuroinflammation in the brain of PD mice upon GDNF-macrophages treatment (B, G) 
compared to PD mice treated with saline (A, F). The administration of sham-transfected 
macrophages (C, H) did not affect the number of activated microglial cells and activated 
astrocytes in PD mice. Values are means ± SEM (N = 6), and *p < 0.05. The bar: 100 μm. 
For detailed statistical comparisons, see Supplementary Tables S10 – S13.
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Figure 7. GDNF-macrophages inhibit formation of proteinase K-resistant α-synuclein in Parkin 
Q311X(A) mice.
Transgenic mice (4 mo. old) were i.v. injected with saline (A), or GDNF-transfected (B), or 
sham-transfected (C) macrophages (2x106 cells/100 μL/mouse, once a week, 3x weeks). WT 
mice were systemically injected with saline (D). Animals were sacrificed at mo. 16, brain 
slides were treated with protease K, and stained with Ab to α-synuclein. Insets on the right 
lower comer are higher-power view of the SNpc area. The obtained confocal images, and 
quantification of α-synuclein staining (E) determined as the function of the positive area by 
ImageJ software for mean Fluorescent Intensity (MFI) and % Area of fluorescence, indicate 
significant reduction of aggregates formation upon treatment with GDNF-macrophages. 
Values are means ± SEM (N = 6), and *p < 0.05. The bar: 100 μm. For detailed statistical 
comparisons, see Supplementary Tables S12 – S13.
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Figure 8. Histological analysis of neuroprotective effects by GDNF-macrophages produce in PD 
mice.
Transgenic mice (16 mo. old) were i.v. injected with GDNF-transfected macrophages (2x106 
cells/100μL/mouse, once a week, 3 x weeks) or saline, or sham macrophages. WT mice, or 
PD mice (16 mo. old) were systemically injected with saline. Animals were sacrificed at mo. 
22, and brain slides were stained with Nissl staining. The obtained bright light images 
indicate neuroprotective effects in the brain of PD mice upon GDNF-macrophages treatment 
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compared to PD mice treated with saline. The administration of sham macrophages did not 
have significant therapeutic effect in PD mice. The bar: 200 μm.
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